Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | F13A1 | P00488 | 1/20 | 0.44 |
| ▸ | TGM2 | P21980 | 1/20 | 0.44 |
| ▸ | TGM1 | P22735 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL500527 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL500535 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL1190328 | 0.93 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL70762 | 0.90 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2621382 | 0.90 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL70761 | 0.90 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2621378 | 0.90 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL15646147 | 0.89 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL8559025 | 0.89 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL8707514 | 0.89 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220403377-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11312957-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-10676740-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20190345498-A1 | MODIFIED iRNA AGENTS | BANK OF AMERICA, N.A. | 2019-11-14 | — | — | US | disclosed |
| US-20180258427-A1 | MODIFIED iRNA AGENTS | BANK OF AMERICA, N.A. | 2018-09-13 | — | — | US | disclosed |
| US-20160264968-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2016-09-15 | — | — | US | disclosed |
| US-20160264968-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2016-09-15 | — | — | US | disclosed |
| US-20160264968-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2016-09-15 | — | — | US | disclosed |
| US-9394540-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-9394540-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| WO-2010022001-A1 | METHODS FOR PREPARING FLUOROALKYL ARYLSULFINYL COMPOUNDS AND FLUORINATED COMPOUNDS THERETO | IM&T RESEARCH, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| EP-1486500-B1 | 10-(3-CYCLOPROPYLAMINOMETHYL-1-PYRROLIDINYL)PYRIDOBENZOXAZINECARBOXYLIC ACID DERIVATIVE EFFECTIVE AGAINST RESISTANT BACTERIA | KYORIN SEIYAKU KK (JP) | 2009-09-16 | — | — | EP | disclosed |
| US-20090176824-A1 | 7- (4-substituted-3-cyclopropylaminomethyl-1-pyrrolidinyl) quinolonecarboxylic acid derivative technical field | ASAHINA YOSHIKAZU | 2009-07-09 | — | — | US | disclosed |
| US-7514451-B2 | 7-(4-Substituted-3-cyclopropylaminomethyl-1 pyrrolidinyl) quinolonecarboxylic acid derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2009-04-07 | — | — | US | disclosed |
| US-7153851-B2 | 10-(3-cyclopropylaminomethyl-1-pyrrolidinyl)pyridobenzoxazinecarboxylic acid derivative effective against resistant bacterium | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2006-12-26 | — | — | US | disclosed |
| US-20060281779-A1 | 7-(4-Substituted-3-cyclopropylaminomethyl-1 pyrrolidinyl) quinolonecarboxylic acid derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2006-12-14 | — | — | US | disclosed |
| EP-1666477-A1 | 7-(4-SUBSTITUTED 3- CYCLOPROPYLAMINOMETHYL-1- PYRROLIDINYL) Q UINOLONECARBOXYLIC ACID DERIVATIVE | Kyorin Pharmaceutical Co., Ltd. (JP) | 2006-06-07 | — | — | EP | disclosed |
| US-20050182052-A1 | 10-(3-cyclopropylaminomethyl-1-pyrrolidinyl)pyridobenzoxazinecarboxylic acid derivative effective against resistant bacterium | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| US-20050107325-A1 | Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue, for drug delivery to entrance into tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; antitumor biodrugs | ALNYLAM PHARMACEUTICALS, INC. | 2005-05-19 | — | — | US | disclosed |
| EP-1486500-A1 | 10-(3-CYCLOPROPYLAMINOMETHYL-1-PYRROLIDINYL)PYRIDOBENZOXAZINECARBOXYLIC ACID DERIVATIVE EFFECTIVE AGAINST RESISTANT BACTERIUM | Kyorin Pharmaceutical Co., Ltd. (JP) | 2004-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176824-A1 | 7- (4-substituted-3-cyclopropylaminomethyl-1-pyrrolidinyl) quinolonecarboxylic acid derivative technical field | CLPP, PRSS1, FOSB | SMN1; SMN2 4463/4885NPC1 4323/4885RAB9A 1331/4885 |
| US-20220403377-A1 | MODIFIED iRNA AGENTS | NCL, HNRNPA0, HNRNPA1 | SMN1; SMN2 2665/4885NPC1 65/4885RAB9A 379/4885 |
| US-20190345498-A1 | MODIFIED iRNA AGENTS | NCL, HNRNPA0, HNRNPA1 | SMN1; SMN2 2665/4885NPC1 65/4885RAB9A 379/4885 |
| US-20060281779-A1 | 7-(4-Substituted-3-cyclopropylaminomethyl-1 pyrrolidinyl) quinolonecarboxylic acid derivative | RPS27L, RPS7, RPSA | SMN1; SMN2 4429/4885NPC1 3419/4885RAB9A 912/4885 |
| US-20180258427-A1 | MODIFIED iRNA AGENTS | NCL, HNRNPA0, HNRNPA1 | SMN1; SMN2 2665/4885NPC1 65/4885RAB9A 379/4885 |
| US-10676740-B2 | Modified iRNA agents | NCL, HNRNPA0, HNRNPA1 | SMN1; SMN2 2665/4885NPC1 65/4885RAB9A 379/4885 |
| US-20050107325-A1 | Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue, for drug delivery to entrance into tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; antitumor biodrugs | LDLR, SLC29A1, SLC29A2 | SMN1; SMN2 2749/4885NPC1 10/4885RAB9A 311/4885 |
| US-11312957-B2 | Modified iRNA agents | NCL, HNRNPA0, HNRNPA1 | SMN1; SMN2 2665/4885NPC1 65/4885RAB9A 379/4885 |
| US-20050182052-A1 | 10-(3-cyclopropylaminomethyl-1-pyrrolidinyl)pyridobenzoxazinecarboxylic acid derivative effective against resistant bacterium | RRP15, RRP12, RRS1 | SMN1; SMN2 4030/4885NPC1 3758/4885RAB9A 1294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.